Home > Press release

 

 

ARCHIVE PRESS RELEASE
Chiesi Group receives European Marketing Authorisation for its triple combination therapy inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) in extrafine fixed formulation delivered through NEXThaler, for the treatment of moderate to severe COPD
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
Chiesi Group: performance is up in 2020
Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support
Chiesi Group receives the European marketing authorisation for Trimbow® (beclometasone dipropionate, formoterol fumarate, glycopyrronium) an extrafine formulation fixed triple combination therapy for the treatment of asthma
Chiesi Headquarters: an innovative, sustainable and people-friendly “home”, the first building in its category to be certified “LEED Platinum” in Italy. A people-oriented project.
“Infermieri, a viso aperto”, a photographic project bringing to light the faces and stories of those who help patients every day
Kaia Health and Chiesi Group Announce Strategic Partnership to Commercialise Kaia COPD Pulmonary Rehabilitation App in European Markets
Chiesi Group receives Diversity Leaders Award 2021
Chiesi launches “The Art of Caring”, a journey in search of the link between Parma, officinal treatments and pharmaceutics